ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ensysce Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.50−0.02 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ensysce Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Market Cap | $9.78M | $164.85M |
| Enterprise Value | $8.78M | $87.06M |
| PS Ratio | 2.17 | 3.60 |
Enterprise value
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| EV / Sales | 1.95 | 2.43 |
Income (trailing twelve months)
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Revenue | $4.50M | $57.94M |
| Operating Income | -$12.66M | -$21.44M |
| EBITDA | -$12.66M | -$16.91M |
| EPS (Diluted) | -$2.75 | -$0.83 |
Margins
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Operating Margin | -281.3% | -44.5% |
| EBITDA Margin | -281.3% | -31.3% |
Growth
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -39.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 26.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.21% | 6.42% |
Balance sheet
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $676.70K | $62.42M |
| Net Cash (Debt) | $676.70K | $15.68M |
| Net Cash Per Share | $0.03 | $0.66 |
| Equity (Book Value) | -$781.70K | $48.79M |
| Book Value Per Share | -$0.04 | $1.36 |
| Tangible Book Value | -$781.70K | $23.06M |
| Working Capital | -$1.22M | $75.77M |
Financial position
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Current Ratio | 0.70 | 3.30 |
| Quick Ratio | 0.17 | 2.39 |
| Interest Coverage | -791.64 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.86M | -$12.35M |
Efficiency
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 1.06 | 0.38 |
| Revenue Per Employee | $562.59K | $398.96K |
| Employee Count | 8 | 74 |
Shares
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 19,456,800 | 58,179,650 |
| Shares Change (YoY) | 381.8% | 11.1% |
| Shares Change (QoQ) | 74.9% | 0.54% |
| Float | 18,250,200 | 49,173,100 |
| Shares Held by Insiders | 6.20% | 11.6% |
| Shares Held by Institutions | 4.65% | 59.4% |
Scores
| Measure | Ensysce Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -80.70 | -0.24 |
Calculated by StockData from Ensysce Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.